H.R. 1492 · 119th Congress
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and…
Full title
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Not yet voted on. This bill is still a proposal: it hasn't reached a floor vote, and its text can change in committee or on the floor before any vote.
R
MurphySponsor68 cosponsors · 4 D, 64 R
D
Davis
RH
R
Hudson
VB
R
Buchanan
DC
R
Crenshaw
ND
R
Dunn
TK
R
Kean
NM
R
Malliotakis
CM
R
Miller
MM
R
Miller-Meeks
TM
R
Moore
CT
R
Tenney
BV
R
Van Duyne
RY
R
Yakym
NM
R
Moran
AP
R
Pfluger
JC
R
Comer
BF
R
Fitzpatrick
AH
R
Harris
AM
R
McDowell
RA
R
Allen
GE
R
Evans
MH
R
Haridopolos
BS
R
Steil
WS
R
Steube
AB
R
Bean
RB
R
Bresnahan
JH
R
Hill
BJ
R
Jack
MK
R
Kelly
BK
R
Knott
RM
R
McCormick
MA
R
Amodei
EH
R
Houchin
AO
R
Ogles
MR
R
Rulli
LS
R
Smucker
RW
R
Weber
KC
R
Cammack
MF
R
Flood
RL
R
Latta
TB
R
Balderson
PH
R
Harrigan
MC
R
Carey
JF
R
Fedorchak
DH
R
Harshbarger
DR
R
Rouzer
JS
R
Shreve
RF
R
Fry
MB
R
Baumgartner
CG
R
Goldman
KH
R
Hern
ZZ
R
(Zach) Nunn
DK
R
Kustoff
SF
R
Fitzgerald
AH
R
Hinson
MF
R
Fischbach
CB
R
Bentz
JC
R
Ciscomani
MK
R
Kennedy
MM
R
Miller
BC
R
Carter
VF
R
Fong
BH
R
Huizenga
JM
R
McGuire
AS
R
Smith
SP
D
Peters
BB
D
Boyle
JM
D
Moskowitz2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.
What it does: CRS summary · Introduced in House · Feb 21, 2025
This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.
The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.
The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation.
The bill's changes apply retroactively.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Latest action (Feb 21, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Policy area: Health · Origin: House · Introduced: Feb 21, 2025
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.